Exact Mass: 521.3199802
Exact Mass Matches: 521.3199802
Found 500 metabolites which its exact mass value is equals to given mass value 521.3199802,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
LysoPC (18:1/0:0)
LysoPC(18:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:19Z)), in particular, consists of one chain of oleic acid at the C-1 position. The oleic acid moiety, an omega-9 fatty acid, is derived from various animal and vegetable sources such as olive oil, acai and grapeseed oil. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. Lysophosphatidylcholines (LPC), also called lysolecithins, are a class of chemical compounds which are derived from phosphatidylcholines. They result from partial hydrolysis of phosphatidylcholines, which removes one of the fatty acid groups. The hydrolysis is generally the result of the enzymatic action of phospholipase A2. LPC is present as a minor phospholipid in the cell membrane (<=3\\%) and in the blood plasma (8-12\\%). Since LPCs are quickly metabolized by lysophosholypase and LPC-acyltransferase, they last only shortly in vivo. [Wikipedia]. Lysolecithin is found in many foods, some of which are cardamom, cucumber, common buckwheat, and rice.
LysoPC(18:1(11Z)/0:0)
LysoPC(18:1(11Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:1(11Z)), in particular, consists of one chain of vaccenic acid at the C-1 position. The vaccenic acid moiety is derived from butter fat and animal fat. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(18:1(11Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:1(11Z)), in particular, consists of one chain of vaccenic acid at the C-1 position. The vaccenic acid moiety is derived from butter fat and animal fat. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
LysoPC(0:0/18:1(9Z))
LysoPC(0:0/18:1(9Z)) is a lysophosphatidylcholine, which is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2 as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. There is also a phospholipase A1, which is able to cleave the sn-1 ester bond. Lysophosphatidylcholine has pro-inflammatory properties in vitro and it is known to be a pathological component of oxidized lipoproteins (LDL) in plasma and of atherosclerotic lesions. Recently, it has been found to have some functions in cell signalling, and specific receptors (coupled to G proteins) have been identified. It activates the specific phospholipase C that releases diacylglycerols and inositol triphosphate with resultant increases in intracellular Ca2+ and activation of protein kinase C. It also activates the mitogen-activated protein kinase in certain cell types. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPC(0:0/18:1(9Z)), in particular, consists of one chain of oleic acid at the C-2 position.
Chenodeoxycholylglutamic acid
Chenodeoxycholylglutamic acid belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylglutamic acid consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Glutamic acid conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylglutamic acid, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylglutamic acid appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylglutamic acid
Deoxycholylglutamic acid belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylglutamic acid consists of the bile acid deoxycholic acid conjugated to the amino acid Glutamic acid conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylglutamic acid, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylglutamic acid appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
2-[2-(17-Amino-5,13,14,16-tetrahydroxy-3,7-dimethylheptadecan-4-yl)oxy-2-oxoethyl]butanedioic acid
Thr Phe Val Arg
C24H39N7O6 (521.2961674000001)
Ile Val Tyr Lys
C26H43N5O6 (521.3213178000001)
Phe Lys Val Glu
(1S,4R,5R,6S,8R,10R,13S,16S,18R)-4-(acetyloxy)-11-ethyl-16-hydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
LPC 18:1
Annotation level-3
Lyso-PC 18:1(9Z)
This mass spectral data is shown in Figure S7 of the publication.; Figure S7 shows that O attached precursor ions, [M+H+O*]+, are predominantly in the epoxide form. The [M+H+O*]+ ion is the product that [M+H]+ reacts with H2O microwave discharge (MSJ00187). The products of microwave discharge are mixture of gas-phase H*, OH*, and 3O (triplet O) radicals.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of HAD, and TOF analyzes the product ions.; MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). FRAGMENTATION_MODE is RID that is Radical Induced Dissociation; MALDI generates [M+H]+ ion, which is dissociated by the reaction with 3O (triplet O) generated by O2 microwave discharge.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data and fragment ions produced are shown in Figure S6_2 of the publication.; Relative intensity of the peaks m/z 180-199 is magnified by x5, those of the peaks m/z 200-507 by 100.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). MSJ00188 is shown in Figure 5 of the publication. The precursor ion is the [M+H+O]+ ion that is a major product ion of the reaction product of [M+H]+ with H2O microwave discharge (MSJ00187). In the present experiment, [M+H+O]+ ions are induced by the injection of 3O (triplet) from the microwave discharge of pure O2 gas.; Figure 5 shows that O attached precursor ions, [M+H+O]+, are predominantly in the epoxide form.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of HAD, and TOF analyzes the product ions.; MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). MALDI generates a stable [M+H]+ ion. [M+H]+ reacts with the mixture of OH* and H* radicals, and 3O (triplet O) atom that microwave discharge of H2O generates. The reaction products, consisting of [M+H+H*], [M+H+O]+ and [M+H+OH*]+ ions, are dissociated to give product ions, which are detected as RID product ions.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure S5 of the publication. Fragment ions produced are explained in Scheme 2 of the publication. MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; Relative Intensity of the peaks is magnified; m/z 180-199 by x5, m/z 200-505 by x100; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). MALDI generates a stable [M+H]+ ion. Microwave discharge of H2O generates OH*, H* and 3O (triplet O) radicals. These radicals react with the stable [M+H]+ ion and give a mixture of [M+H+H*], [M+H+O]+ and [M+H+OH*]+ ions. In the present experiment, O2 gas is introduced after the H2O discharge.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure 4(C) of the publication. Fragment ions produced are annotated in Scheme 2 of the publication. MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; Relative intensity of the peaks from m/z 300 to 499 is magnified by x10.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). RID is Radical Induced Dissociation; MALDI generates [M+H]+ ion, which is dissociated by the reaction with 3O (triplet O) generated by O2 microwave discharge.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure 4(B) of the publication. Fragment ions produced are annotated in Scheme 2. MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; Relative Intensity of the peaks from m/z 300 to 499 is magnified by x10.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). What is Radical Induced Dissociation (RID)? Microwave discharge of H2O generates OH*, H* and 3O (triplet O) radicals. These radicals react to dissociate the stable [M+H]+ ion.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure 4(A) of the publication. Fragment ions produced are annotated in Scheme 2. MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; Relative intensity of the peaks from m/z 300 to 499 is magnified by x100.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). This is an experiment to compare with MSJ00179 that uses Hydrogen Abstraction Dissociation (HAD) instead of CID for the dissociation of [M+H]+.; This mass spectral data is shown in Figure S3 of the publication.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of HAD, and TOF analyzes the product ions.; MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; The sample was injected by direct infusion.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). FRAGMENTATION_MODE is HAD that is Hydrogen Abstraction Dissociation; MALDI generates [M+H]+ ion, which is dissociated by the reaction with hydrogen radical (H*) generated by microwave-driven radical generator.; This mass spectral data is shown in Figure 1(A) of the publication.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of HAD, and TOF analyzes the product ions.; MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; The sample was injected by direct infusion.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). This mass spectral data is shown in Figure 1(A) Inset of the publication.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL).
(1S,4R,5R,6S,8R,10R,13S,16S,18R)-4-(acetyloxy)-11-ethyl-16-hydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate_major
Ala Ile Arg Tyr
C24H39N7O6 (521.2961674000001)
Ala Ile Tyr Arg
C24H39N7O6 (521.2961674000001)
Ala Leu Arg Tyr
C24H39N7O6 (521.2961674000001)
Ala Leu Tyr Arg
C24H39N7O6 (521.2961674000001)
Ala Arg Ile Tyr
C24H39N7O6 (521.2961674000001)
Ala Arg Leu Tyr
C24H39N7O6 (521.2961674000001)
Ala Arg Tyr Ile
C24H39N7O6 (521.2961674000001)
Ala Arg Tyr Leu
C24H39N7O6 (521.2961674000001)
Ala Tyr Ile Arg
C24H39N7O6 (521.2961674000001)
Ala Tyr Leu Arg
C24H39N7O6 (521.2961674000001)
Ala Tyr Arg Ile
C24H39N7O6 (521.2961674000001)
Ala Tyr Arg Leu
C24H39N7O6 (521.2961674000001)
Asp Phe Ile Lys
Asp Phe Lys Ile
Asp Phe Lys Leu
Asp Phe Leu Lys
Asp Ile Phe Lys
Asp Ile Lys Phe
Asp Lys Phe Ile
Asp Lys Phe Leu
Asp Lys Ile Phe
Asp Lys Leu Phe
Asp Leu Phe Lys
Asp Leu Lys Phe
Glu Phe Lys Val
Glu Phe Val Lys
Glu Lys Phe Val
Glu Lys Val Phe
Glu Val Phe Lys
Glu Val Lys Phe
Phe Asp Ile Lys
Phe Asp Lys Ile
Phe Asp Lys Leu
Phe Asp Leu Lys
Phe Glu Lys Val
Phe Glu Val Lys
Phe Ile Asp Lys
Phe Ile Lys Asp
Phe Ile Arg Ser
C24H39N7O6 (521.2961674000001)
Phe Ile Ser Arg
C24H39N7O6 (521.2961674000001)
Phe Lys Asp Ile
Phe Lys Asp Leu
Phe Lys Glu Val
Phe Lys Ile Asp
Phe Lys Leu Asp
Phe Leu Asp Lys
Phe Leu Lys Asp
Phe Leu Arg Ser
C24H39N7O6 (521.2961674000001)
Phe Leu Ser Arg
C24H39N7O6 (521.2961674000001)
Phe Arg Ile Ser
C24H39N7O6 (521.2961674000001)
Phe Arg Leu Ser
C24H39N7O6 (521.2961674000001)
Phe Arg Ser Ile
C24H39N7O6 (521.2961674000001)
Phe Arg Ser Leu
C24H39N7O6 (521.2961674000001)
Phe Arg Thr Val
C24H39N7O6 (521.2961674000001)
Phe Arg Val Thr
C24H39N7O6 (521.2961674000001)
Phe Ser Ile Arg
C24H39N7O6 (521.2961674000001)
Phe Ser Leu Arg
C24H39N7O6 (521.2961674000001)
Phe Ser Arg Ile
C24H39N7O6 (521.2961674000001)
Phe Ser Arg Leu
C24H39N7O6 (521.2961674000001)
Phe Thr Arg Val
C24H39N7O6 (521.2961674000001)
Phe Thr Val Arg
C24H39N7O6 (521.2961674000001)
Phe Val Glu Lys
Phe Val Lys Glu
Phe Val Arg Thr
C24H39N7O6 (521.2961674000001)
Phe Val Thr Arg
C24H39N7O6 (521.2961674000001)
His Ile Pro Arg
His Ile Arg Pro
His Leu Pro Arg
His Leu Arg Pro
His Pro Ile Arg
His Pro Leu Arg
His Pro Arg Ile
His Pro Arg Leu
His Arg Ile Pro
His Arg Leu Pro
His Arg Pro Ile
His Arg Pro Leu
Ile Ala Arg Tyr
C24H39N7O6 (521.2961674000001)
Ile Ala Tyr Arg
C24H39N7O6 (521.2961674000001)
Ile Asp Phe Lys
Ile Asp Lys Phe
Ile Phe Asp Lys
Ile Phe Lys Asp
Ile Phe Arg Ser
C24H39N7O6 (521.2961674000001)
Ile Phe Ser Arg
C24H39N7O6 (521.2961674000001)
Ile His Pro Arg
Ile His Arg Pro
Ile Ile Asn Tyr
Ile Ile Tyr Asn
Ile Lys Asp Phe
Ile Lys Phe Asp
Ile Lys Val Tyr
C26H43N5O6 (521.3213178000001)
Ile Lys Tyr Val
C26H43N5O6 (521.3213178000001)
Ile Leu Asn Tyr
Ile Leu Tyr Asn
Ile Asn Ile Tyr
Ile Asn Leu Tyr
Ile Asn Tyr Ile
Ile Asn Tyr Leu
Ile Pro His Arg
Ile Pro Arg His
Ile Gln Val Tyr
Ile Gln Tyr Val
Ile Arg Ala Tyr
C24H39N7O6 (521.2961674000001)
Ile Arg Phe Ser
C24H39N7O6 (521.2961674000001)
Ile Arg His Pro
Ile Arg Pro His
Ile Arg Ser Phe
C24H39N7O6 (521.2961674000001)
Ile Arg Tyr Ala
C24H39N7O6 (521.2961674000001)
Ile Ser Phe Arg
C24H39N7O6 (521.2961674000001)
Ile Ser Arg Phe
C24H39N7O6 (521.2961674000001)
Ile Val Lys Tyr
C26H43N5O6 (521.3213178000001)
Ile Val Gln Tyr
Ile Val Tyr Gln
Ile Tyr Ala Arg
C24H39N7O6 (521.2961674000001)
Ile Tyr Ile Asn
Ile Tyr Lys Val
C26H43N5O6 (521.3213178000001)
Ile Tyr Leu Asn
Ile Tyr Asn Ile
Ile Tyr Asn Leu
Ile Tyr Gln Val
Ile Tyr Arg Ala
C24H39N7O6 (521.2961674000001)
Ile Tyr Val Lys
C26H43N5O6 (521.3213178000001)
Ile Tyr Val Gln
Lys Asp Phe Ile
Lys Asp Phe Leu
Lys Asp Ile Phe
Lys Asp Leu Phe
Lys Glu Phe Val
Lys Glu Val Phe
Lys Phe Asp Ile
Lys Phe Asp Leu
Lys Phe Glu Val
Lys Phe Ile Asp
Lys Phe Leu Asp
Lys Phe Val Glu
Lys Ile Asp Phe
Lys Ile Phe Asp
Lys Ile Val Tyr
C26H43N5O6 (521.3213178000001)
Lys Ile Tyr Val
C26H43N5O6 (521.3213178000001)
Lys Leu Asp Phe
Lys Leu Phe Asp
Lys Leu Val Tyr
C26H43N5O6 (521.3213178000001)
Lys Leu Tyr Val
C26H43N5O6 (521.3213178000001)
Lys Val Glu Phe
Lys Val Phe Glu
Lys Val Ile Tyr
C26H43N5O6 (521.3213178000001)
Lys Val Leu Tyr
C26H43N5O6 (521.3213178000001)
Lys Val Tyr Ile
C26H43N5O6 (521.3213178000001)
Lys Val Tyr Leu
C26H43N5O6 (521.3213178000001)
Lys Tyr Ile Val
C26H43N5O6 (521.3213178000001)
Lys Tyr Leu Val
C26H43N5O6 (521.3213178000001)
Lys Tyr Val Ile
C26H43N5O6 (521.3213178000001)
Lys Tyr Val Leu
C26H43N5O6 (521.3213178000001)
Leu Ala Arg Tyr
C24H39N7O6 (521.2961674000001)
Leu Ala Tyr Arg
C24H39N7O6 (521.2961674000001)
Leu Asp Phe Lys
Leu Asp Lys Phe
Leu Phe Asp Lys
Leu Phe Lys Asp
Leu Phe Arg Ser
C24H39N7O6 (521.2961674000001)
Leu Phe Ser Arg
C24H39N7O6 (521.2961674000001)
Leu His Pro Arg
Leu His Arg Pro
Leu Ile Asn Tyr
Leu Ile Tyr Asn
Leu Lys Asp Phe
Leu Lys Phe Asp
Leu Lys Val Tyr
C26H43N5O6 (521.3213178000001)
Leu Lys Tyr Val
C26H43N5O6 (521.3213178000001)
Leu Leu Asn Tyr
Leu Pro His Arg
Leu Pro Arg His
Leu Arg Ala Tyr
C24H39N7O6 (521.2961674000001)
Leu Arg Phe Ser
C24H39N7O6 (521.2961674000001)
Leu Arg His Pro
Leu Arg Pro His
Leu Arg Ser Phe
C24H39N7O6 (521.2961674000001)
Leu Arg Tyr Ala
C24H39N7O6 (521.2961674000001)
Leu Ser Phe Arg
C24H39N7O6 (521.2961674000001)
Leu Ser Arg Phe
C24H39N7O6 (521.2961674000001)
Leu Val Lys Tyr
C26H43N5O6 (521.3213178000001)
Leu Val Tyr Lys
C26H43N5O6 (521.3213178000001)
Leu Tyr Ala Arg
C24H39N7O6 (521.2961674000001)
Leu Tyr Lys Val
C26H43N5O6 (521.3213178000001)
Leu Tyr Arg Ala
C24H39N7O6 (521.2961674000001)
Leu Tyr Val Lys
C26H43N5O6 (521.3213178000001)
Pro His Ile Arg
Pro His Leu Arg
Pro His Arg Ile
Pro His Arg Leu
Pro Ile His Arg
Pro Ile Arg His
Pro Leu His Arg
Pro Leu Arg His
Pro Arg His Ile
Pro Arg His Leu
Pro Arg Ile His
Pro Arg Leu His
Arg Ala Ile Tyr
C24H39N7O6 (521.2961674000001)
Arg Ala Leu Tyr
C24H39N7O6 (521.2961674000001)
Arg Ala Tyr Ile
C24H39N7O6 (521.2961674000001)
Arg Ala Tyr Leu
C24H39N7O6 (521.2961674000001)
Arg Phe Ile Ser
C24H39N7O6 (521.2961674000001)
Arg Phe Leu Ser
C24H39N7O6 (521.2961674000001)
Arg Phe Ser Ile
C24H39N7O6 (521.2961674000001)
Arg Phe Ser Leu
C24H39N7O6 (521.2961674000001)
Arg Phe Thr Val
C24H39N7O6 (521.2961674000001)
Arg Phe Val Thr
C24H39N7O6 (521.2961674000001)
Arg His Ile Pro
Arg His Leu Pro
Arg His Pro Ile
Arg His Pro Leu
Arg Ile Ala Tyr
C24H39N7O6 (521.2961674000001)
Arg Ile Phe Ser
C24H39N7O6 (521.2961674000001)
Arg Ile His Pro
Arg Ile Pro His
Arg Ile Ser Phe
C24H39N7O6 (521.2961674000001)
Arg Ile Tyr Ala
C24H39N7O6 (521.2961674000001)
Arg Leu Ala Tyr
C24H39N7O6 (521.2961674000001)
Arg Leu Phe Ser
C24H39N7O6 (521.2961674000001)
Arg Leu His Pro
Arg Leu Pro His
Arg Leu Ser Phe
C24H39N7O6 (521.2961674000001)
Arg Leu Tyr Ala
C24H39N7O6 (521.2961674000001)
Arg Pro His Ile
Arg Pro His Leu
Arg Pro Ile His
Arg Pro Leu His
Arg Ser Phe Ile
C24H39N7O6 (521.2961674000001)
Arg Ser Phe Leu
C24H39N7O6 (521.2961674000001)
Arg Ser Ile Phe
C24H39N7O6 (521.2961674000001)
Arg Ser Leu Phe
C24H39N7O6 (521.2961674000001)
Arg Thr Phe Val
C24H39N7O6 (521.2961674000001)
Arg Thr Val Phe
C24H39N7O6 (521.2961674000001)
Arg Val Phe Thr
C24H39N7O6 (521.2961674000001)
Arg Val Thr Phe
C24H39N7O6 (521.2961674000001)
Arg Tyr Ala Ile
C24H39N7O6 (521.2961674000001)
Arg Tyr Ala Leu
C24H39N7O6 (521.2961674000001)
Arg Tyr Ile Ala
C24H39N7O6 (521.2961674000001)
Arg Tyr Leu Ala
C24H39N7O6 (521.2961674000001)
Ser Phe Ile Arg
C24H39N7O6 (521.2961674000001)
Ser Phe Leu Arg
C24H39N7O6 (521.2961674000001)
Ser Phe Arg Ile
C24H39N7O6 (521.2961674000001)
Ser Phe Arg Leu
C24H39N7O6 (521.2961674000001)
Ser Ile Phe Arg
C24H39N7O6 (521.2961674000001)
Ser Ile Arg Phe
C24H39N7O6 (521.2961674000001)
Ser Leu Phe Arg
C24H39N7O6 (521.2961674000001)
Ser Leu Arg Phe
C24H39N7O6 (521.2961674000001)
Ser Arg Phe Ile
C24H39N7O6 (521.2961674000001)
Ser Arg Phe Leu
C24H39N7O6 (521.2961674000001)
Ser Arg Ile Phe
C24H39N7O6 (521.2961674000001)
Ser Arg Leu Phe
C24H39N7O6 (521.2961674000001)
Thr Phe Arg Val
C24H39N7O6 (521.2961674000001)
Thr Arg Phe Val
C24H39N7O6 (521.2961674000001)
Thr Arg Val Phe
C24H39N7O6 (521.2961674000001)
Thr Val Phe Arg
C24H39N7O6 (521.2961674000001)
Thr Val Arg Phe
C24H39N7O6 (521.2961674000001)
Val Phe Arg Thr
C24H39N7O6 (521.2961674000001)
Val Phe Thr Arg
C24H39N7O6 (521.2961674000001)
Val Ile Lys Tyr
C26H43N5O6 (521.3213178000001)
Val Ile Tyr Lys
C26H43N5O6 (521.3213178000001)
Val Lys Ile Tyr
C26H43N5O6 (521.3213178000001)
Val Lys Leu Tyr
C26H43N5O6 (521.3213178000001)
Val Lys Tyr Ile
C26H43N5O6 (521.3213178000001)
Val Lys Tyr Leu
C26H43N5O6 (521.3213178000001)
Val Leu Lys Tyr
C26H43N5O6 (521.3213178000001)
Val Leu Tyr Lys
C26H43N5O6 (521.3213178000001)
Val Arg Phe Thr
C24H39N7O6 (521.2961674000001)
Val Arg Thr Phe
C24H39N7O6 (521.2961674000001)
Val Thr Phe Arg
C24H39N7O6 (521.2961674000001)
Val Thr Arg Phe
C24H39N7O6 (521.2961674000001)
Val Tyr Ile Lys
C26H43N5O6 (521.3213178000001)
Val Tyr Lys Ile
C26H43N5O6 (521.3213178000001)
Val Tyr Lys Leu
C26H43N5O6 (521.3213178000001)
Val Tyr Leu Lys
C26H43N5O6 (521.3213178000001)
Tyr Ala Ile Arg
C24H39N7O6 (521.2961674000001)
Tyr Ala Leu Arg
C24H39N7O6 (521.2961674000001)
Tyr Ala Arg Ile
C24H39N7O6 (521.2961674000001)
Tyr Ala Arg Leu
C24H39N7O6 (521.2961674000001)
Tyr Ile Ala Arg
C24H39N7O6 (521.2961674000001)
Tyr Ile Lys Val
C26H43N5O6 (521.3213178000001)
Tyr Ile Arg Ala
C24H39N7O6 (521.2961674000001)
Tyr Ile Val Lys
C26H43N5O6 (521.3213178000001)
Tyr Lys Ile Val
C26H43N5O6 (521.3213178000001)
Tyr Lys Leu Val
C26H43N5O6 (521.3213178000001)
Tyr Lys Val Ile
C26H43N5O6 (521.3213178000001)
Tyr Lys Val Leu
C26H43N5O6 (521.3213178000001)
Tyr Leu Ala Arg
C24H39N7O6 (521.2961674000001)
Tyr Leu Lys Val
C26H43N5O6 (521.3213178000001)
Tyr Leu Arg Ala
C24H39N7O6 (521.2961674000001)
Tyr Leu Val Lys
C26H43N5O6 (521.3213178000001)
Tyr Arg Ala Ile
C24H39N7O6 (521.2961674000001)
Tyr Arg Ala Leu
C24H39N7O6 (521.2961674000001)
Tyr Arg Ile Ala
C24H39N7O6 (521.2961674000001)
Tyr Arg Leu Ala
C24H39N7O6 (521.2961674000001)
Tyr Val Ile Lys
C26H43N5O6 (521.3213178000001)
Tyr Val Lys Ile
C26H43N5O6 (521.3213178000001)
Tyr Val Lys Leu
C26H43N5O6 (521.3213178000001)
Tyr Val Leu Lys
C26H43N5O6 (521.3213178000001)
Platelet-activating factor
PC(P-16:0/2:0)
PC(18:1/0:0)
PC(18:1/0:0)[U]
PC(0:0/18:1)
Elaidin, 2-mono-,
PC(0:0/18:1)[U]
4-[(9-cyclopentyl-5,8-dimethyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide
14-(Acetyloxy)-20-ethyl-1-hydroxy-6,16-dimethoxy-4-(methoxymethyl)aconitan-8-yl acetate
1-Elaidoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:1 in which the acyl group is at position 1 is elaidoyl [(9E)-octadec-9-enoyl] and the hydoxy group at position 2 is unsubstituted.
(1S,2R,5S,7S,12S,15S)-1,2-dimethyl-7-[2-(3-methylbut-2-enoxy)propan-2-yl]-6,10-dioxa-24-azaheptacyclo[13.10.0.02,12.05,11.09,11.017,25.018,23]pentacosa-17(25),18,20,22-tetraene-8,12-diol
2-C22:0-alpha,omega-dicaboxyl-lysophosphatidic acid
[2-hydroxy-3-[(E)-octadec-6-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(2R)-2-(acetyloxy)-3-{[(9Z)-hexadec-9-en-1-yl]oxy}propyl 2-(trimethylazaniumyl)ethyl phosphate
[2-hydroxy-3-[(E)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
propan-2-yl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
propan-2-yl N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
propan-2-yl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
[2-acetyloxy-3-[(Z)-hexadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2S)-3-hydroxy-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(Z)-16,16,17,17,18,18,18-heptadeuteriooctadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-henicos-11-enoate
[2-pentanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] octanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] hexanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (Z)-tridec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] acetate
[3-[(Z)-pentadec-9-enoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]undec-4-ene-1-sulfonic acid
(4E,8E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxytrideca-4,8-diene-1-sulfonic acid
4-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-propanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] heptanoate
[2-butanoyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] pentanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] propanoate
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (Z)-tetradec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (Z)-tridec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-heptadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (Z)-hexadec-9-enoate
[3-acetyloxy-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-butanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-propanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(1S,4R,5R,6S,8R,10R,13S,16S,17R,18R)-8-acetyloxy-11-ethyl-16-hydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] acetate
[(2R)-2-hydroxy-3-[(E)-octadec-6-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(E)-octadec-4-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-octadec-17-enoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(E)-octadec-11-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(E)-octadec-13-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(E)-octadec-7-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
Terpendole J
An organic heteroheptacyclic compound isolated from Albophoma yamanashiensis and has been shown to exhibit inhibitory activity against acyl-CoA:cholesterol acyltransferase.
2-Oleoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:1 in which the acyl group is specified as oleoyl and is located at position 2.
Lysophosphatidylcholine 18:1
A lysophosphatidylcholine in which the remaining acyl group (position not specified) contains 18 carbons with 1 double bond.
1-O-Oleoyl-sn-glycero-3-phosphocholine
An oleoyl-sn-glycero-3-phosphocholine in which the acyl group at position 1 is (9Z)-octadecenoyl (oleoyl) and the hydroxy group at position 2 is unsubstituted. A lysophosphatidylcholine 18:1 in which the acyl group at position 1 is (9Z)-octadecenoyl and the hydroxy group at position 2 is unsubstituted.
lysophosphatidylcholine (18:1/0:0)
A lysophosphatidylcholine 18:1 in which the acyl group is located at position 1.
lysophosphatidylcholine (0:0/18:1)
A lysophosphatidylcholine 18:1 in which the acyl group is located at position 2.
oleoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:1 in which the acyl group is specified as oleoyl and is located at either position 1 or 2.
1-[(9Z)-hexadecenyl]-2-acetyl-sn-glycero-3-phosphocholine
A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as (9Z)-hexadecenyl.
1-[(11Z)-octadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:1 in which the acyl group specified as position 1 is (11Z)-octadecenoyl.
MePC(17:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(17:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(1s,2r,5s,7s,8r,9r,11s,12s,15s)-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-19-(3-methylbut-2-en-1-yl)-6,10-dioxa-24-azaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁹,¹¹.0¹⁷,²⁵.0¹⁸,²³]pentacosa-17(25),18,20,22-tetraene-8,12-diol
2-{2-[(17-amino-5,13,14,16-tetrahydroxy-3,7-dimethylheptadecan-4-yl)oxy]-2-oxoethyl}butanedioic acid
2-{[(1-{[(3z,9z)-2,7-dihydroxy-5-isopropyl-1,6-diazacyclododeca-1,3,6,9-tetraen-8-yl]-c-hydroxycarbonimidoyl}-2-methylbutyl)-c-hydroxycarbonimidoyl]amino}-3-methylpentanoic acid
C26H43N5O6 (521.3213178000001)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17r,18s)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl (2r)-2-methylbutanoate
(11e,13e)-6-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-15-(hydroxymethyl)-5,7,9-trimethyl-1-oxacyclohexadeca-3,11,13-triene-2,10-dione
1,2-dimethyl-7-{2-[(3-methylbut-2-en-1-yl)oxy]propan-2-yl}-6,10-dioxa-24-azaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁹,¹¹.0¹⁷,²⁵.0¹⁸,²³]pentacosa-17(25),18,20,22-tetraene-8,12-diol
4-(acetyloxy)-11-ethyl-16-hydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
(1s,2r,3r,4s,5r,6s,8r,9r,10r,13s,16s,17r,18r)-4-(acetyloxy)-11-ethyl-16-hydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
2-[({1-[(2,7-dihydroxy-5-isopropyl-1,6-diazacyclododeca-1,3,6,9-tetraen-8-yl)-c-hydroxycarbonimidoyl]-2-methylbutyl}-c-hydroxycarbonimidoyl)amino]-3-methylpentanoic acid
C26H43N5O6 (521.3213178000001)